MA (EU) number 
(Invented)
name
Strength  Pharmaceutical
Form
Route of
Administration
Immediate
Packaging
Content 
(concentration)
Pack size
EU/1/15/1079/001  Vaxelis   
EU/1/15/1079/002  Vaxelis   
EU/1/15/1079/003  Vaxelis   
EU/1/15/1079/004  Vaxelis   
EU/1/15/1079/005  Vaxelis   
EU/1/15/1079/006  Vaxelis   
EU/1/15/1079/007  Vaxelis   
EU/1/15/1079/008  Vaxelis   
--¹
--¹
--¹
--¹
--¹
--¹
--¹
--¹
--¹  One dose (0.5 ml) contains:
Suspension for
injection
Suspension for
injection
Suspension for
injection
Suspension for
injection
Suspension for
injection
Suspension for
injection
Suspension for
injection
Suspension for
injection
Intramuscular use  pre-filled syringe 
0.5 ml
1 pre-filled syringe 
(glass)
Intramuscular use  pre-filled syringe 
0.5 ml
10 pre-filled syringes 
Intramuscular use  pre-filled syringe 
0.5 ml
(glass)
(glass)
Intramuscular use  pre-filled syringe 
0.5 ml
(glass)
Intramuscular use  pre-filled syringe 
0.5 ml
(glass)
Intramuscular use  pre-filled syringe 
0.5 ml
(glass)
Intramuscular use  pre-filled syringe 
0.5 ml
(glass)
Intramuscular use  vial (glass) 
0.5 ml
1 pre-filled syringe + 1
needle 
1 pre-filled syringe + 2
needles 
10 pre-filled syringes
+ 10 needles 
10 pre-filled syringes
+ 20 needles 
50 (5x10) pre-filled
syringes (multipack) 
10 vials
    not less than 20 IU6
    not less than 40 IU6
     20 micrograms
     20 micrograms
                 3 micrograms
      5 micrograms
    10 micrograms
Diphtheria Toxoid¹: 
Tetanus Toxoid¹: 
Bordetella pertussis antigens¹:
     Pertussis Toxoid (PT)  
     Filamentous Haemagglutinin (FHA)  
     Pertactin (PRN)  
     Fimbriae Types 2 and 3 (FIM)  
Hepatitis B surface antigen²,³: 
Poliovirus (Inactivated)4:
     Type 1 (Mahoney)   
     Type 2 (MEF-1)  
     Type 3 (Saukett)    
Haemophilus influenzae type b polysaccharide
     (Polyribosylribitol Phosphate)  
     Conjugated to meningococcal protein²  
¹ adsorbed on aluminium phosphate (0.17 mg Al³+)
² adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.15 mg Al³+)
³ produced in yeast (Saccharomyces cerevisiae) cells by recombinant DNA technology
4 produced in Vero cells 
5 or equivalent antigenic quantity determined by a suitable immunochemical method
6 or equivalent activity determined by an immunogenicity evaluation.
                 40 D antigen units5; 
                   8 D antigen units5 
                 32 D antigen units5
              3 micrograms 
50 micrograms
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
